Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
暂无分享,去创建一个
Michael Thomas | Takashi Seto | Kazuhiko Nakagawa | Myung-Ju Ahn | Gregory J Riely | D Ross Camidge | P. Jänne | K. O'Byrne | Michael Thomas | A. Shaw | M. Ahn | T. Mok | Yi-long Wu | Gregory Riely | K. Wilner | L. Crinò | B. Solomon | D. Camidge | Dong-Wan Kim | T. De Pas | F. Blackhall | D. Moro-Sibilot | B. Besse | T. Seto | K. Nakagawa | V. Hirsh | S. Iyer | Pasi A Jänne | Keith D Wilner | Benjamin Besse | Fiona Blackhall | Tony Mok | Yi-Long Wu | Alice T Shaw | Vanessa Tassell | Vera Hirsh | V. Tassell | A. Polli | Dong-Wan Kim | Kenneth J O'Byrne | Denis Moro-Sibilot | Lucio Crinó | Tommaso De Pas | Benjamin J Solomon | Shrividya Iyer | Anna Polli | T. de Pas | T. D. De Pas
[1] C. Dooms,et al. Prevalence and Clinical Outcomes for Patients With ALK Gene Rearrangement in Europe: Preliminary Results from the European Thoracic Oncology Platform Lungscape Project , 2012 .
[2] J. Ferlay,et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008 , 2013, International journal of cancer.
[3] Jeffrey W. Clark,et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.
[4] A. Reuben. Hy's law , 2004, Hepatology.
[5] J. Dancey,et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[7] Masahiro Fukuoka,et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Jeffrey W. Clark,et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[11] M. Lim,et al. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study. , 2012 .
[12] G. Scagliotti,et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. , 2009, The oncologist.
[13] Ross Camidge,et al. The European Organisation for Research and Treatment of Cancer , 2002 .
[14] C. Messa,et al. Crizotinib in anaplastic large-cell lymphoma. , 2011, The New England journal of medicine.
[15] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[16] S. Kaasa,et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. , 1994, European journal of cancer.
[17] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[18] Miklos Pless,et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Doebele,et al. Treating ALK-positive lung cancer—early successes and future challenges , 2012, Nature Reviews Clinical Oncology.
[20] Laura A. Sullivan,et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.
[21] L. Tanoue,et al. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .
[22] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[23] Y. Bang,et al. Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] A. Shaw,et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). , 2012 .
[25] Jeffrey W. Clark,et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.
[26] A. Tsao,et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .
[27] T. Spiro,et al. Pulmonary toxicities of tyrosine kinase inhibitors. , 2011, Clinical advances in hematology & oncology : H&O.
[28] L. Tanoue,et al. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer , 2007 .
[29] L. Tanoue. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .
[30] A. Sihoe,et al. The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.
[31] W. Franklin,et al. Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.